Accounts Receivable, after Allowance for Credit Loss, Current of Poseida Therapeutics, Inc. from 30 Jun 2022 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Poseida Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 30 Jun 2022 to 30 Sep 2024.
  • Poseida Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2024 was $14,749,000, a 70% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Poseida Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $14,749,000 +$6,077,000 +70% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $12,427,000 +$521,000 +4.4% 30 Jun 2024 10-Q 05 Aug 2024 2024 Q2
Q1 2024 $12,027,000 +$3,590,000 +43% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $9,010,000 -$78,000 -0.86% 31 Dec 2023 10-Q 07 Nov 2024 2024 Q3
Q3 2023 $8,672,000 -$29,795,000 -77% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $11,906,000 +$11,674,000 +5032% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $8,437,000 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $9,088,000 31 Dec 2022 10-K 07 Mar 2024 2023 FY
Q3 2022 $38,467,000 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $232,000 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.